Ziekte van Parkinson en parkinsonisme

Item does not contain fulltex

De cutaneomusculaire reflexen: een onderzoek aan de hand van EMG-registratie van de flexiereflex

Contains fulltext : mmubn000001_027004031.pdf (publisher's version ) (Open Access)Promotor : S. Notermans191 p

De ziekte van Parkinson op latere leeftijd

Item does not contain fulltex

Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.

Contains fulltext : 83236.pdf (author's version ) (Open Access)It is well known that long-term use of levodopa by patients with Parkinson's disease causes dyskinesia. Several methods have been proposed for the automatic, unsupervised detection and classification of levodopa induced dyskinesia. Recently, we have demonstrated that neural networks are highly successful to detect dyskinesia and to distinguish dyskinesia from voluntary movements. The aim of this study was to use the trained neural networks to extract parameters, which are important to distinguish between dyskinesia and voluntary movements.Thirteen patients were continuously monitored in a home-like situation performing in about 35 daily life tasks for a period of approximately 2.5 h. Behavior of the patients was measured using triaxial accelerometers, which were placed at six different positions of the body. A neural network was trained to assess the severity of dyskinesia. The neural network was able to assess the severity of dyskinesia and could distinguish dyskinesia from voluntary movements in daily life. For the trunk and the leg, the important parameters appeared to be the percentage of time that the trunk or leg was moving and the standard deviation of the segment velocity of the less dyskinetic leg. For the arm, the combination of the percentage of time, that the wrist was moving, and the percentage of time, that a patient was sitting, explained the largest part of the variance of the output. Dyskinesia differs from voluntary movements in the fact that dyskinetic movements tend to have lower frequencies than voluntary movements and in the fact that movements of different body segments are not well coordinated in dyskinesia

Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

In this review, we relate both laboratory and clinical evidence associated with the capacity for estrogen to function as a modulator of nigrostriatal dopaminergic pathology. To accomplish this goal, we have divided this review into three parts. In Part 1, we provide a brief historical perspective of studies that have laid the groundwork for demonstrating the existence of hormonal- nigrostriatal interactions. In Part 2, we focus specifically on laboratory data that show the ability and conditions by which estrogen may function as a neuroprotectant of the nigrostriatal dopaminergic system. Finally, in Part 3, we review the clinical literature related to this issue as a means for consideration of estrogen as a modulator, neuroprotectant, and therapy for Parkinson disease

Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease

Item does not contain fulltex

International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease

Contains fulltext : 24152___.PDF (publisher's version ) (Open Access

Movement-related potential measures of different modes of movement selection in Parkinson's disease

Contains fulltext : 22534___.PDF (publisher's version ) (Open Access

Preclinical diagnosis in Parkinson's disease.

Item does not contain fulltex

The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic.

Item does not contain fulltex